Author: Pedersen, Niels C; Perron, Michel; Bannasch, Michael; Montgomery, Elizabeth; Murakami, Eisuke; Liepnieks, Molly; Liu, Hongwei
Title: Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis Document date: 2019_2_13
ID: tkw258dc_20
Snippet: Four cats were euthanized (CT62, CT72, CT75) or died (CT56) within the first 2-5 days because of severe disease and other complications, and a fifth cat was euthanized (CT54) after 26 days owing to a lack of treatment response ( Figure 1 ). Treatment periods were not interrupted except for three cats that were given 2 week respites at week 4 (cat CT80) or week 8 (cats CT53, CT71) because of problems with giving injections and skin reactions ( Fig.....
Document: Four cats were euthanized (CT62, CT72, CT75) or died (CT56) within the first 2-5 days because of severe disease and other complications, and a fifth cat was euthanized (CT54) after 26 days owing to a lack of treatment response ( Figure 1 ). Treatment periods were not interrupted except for three cats that were given 2 week respites at week 4 (cat CT80) or week 8 (cats CT53, CT71) because of problems with giving injections and skin reactions ( Figure 1 ). Cat CT53 was treated after a second relapse for 8 rather than 12 weeks because of a rise in blood urea and serum levels of symmetric dimethylarginine (SDMA).
Search related documents:
Co phrase search for related documents- blood urea and severe disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33
- blood urea and symmetric dimethylarginine: 1, 2
- blood urea and treatment period: 1, 2
- blood urea and treatment response: 1, 2, 3
- complication severe disease and severe disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46
- fifth cat and severe disease: 1, 2
- second relapse and severe disease: 1
- serum level and severe disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60
- serum level and skin reaction: 1, 2
- serum level and symmetric dimethylarginine: 1
- serum level and treatment period: 1, 2, 3, 4
- serum level and treatment response: 1, 2, 3, 4, 5, 6, 7, 8, 9
- severe disease and skin reaction: 1
- severe disease and treatment period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37
- severe disease and treatment response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- severe disease and treatment response lack: 1, 2
- symmetric dimethylarginine and treatment response: 1
Co phrase search for related documents, hyperlinks ordered by date